EN DE
Watch Integra LifeSciences Holdings for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Integra LifeSciences Holdings (IART) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Integra LifeSciences Holdings stock $16.51, price $13.42, upside +23.0%, quality 36 out of 100. Rating: undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

IL Integra LifeSciences Holdings logo Some data Nov 5, 2026

Integra LifeSciences Holdings

IART · US
Speculative

The stock costs 19% less than our calculation considers fair.

Fair value $16.51 · Undervalued (19%)
Upbeat coverage
Expensive Growth (revenue 5y +3.6 %/yr in USD)
Thin margins · 0.8% net margin (TTM)
Some data
Costs 79 times its yearly profit.
Quality 36/100
High debt
Negative free cash flow
Trails peers (4/12)
Narrow moat 27/100
Watch Integra LifeSciences Holdings for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$76.19 $8.90 Fair Value $16.51 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.

How to read this chart

60‑month range $8.90 – $76.19 · fair‑value band $6.60 – $26.42 · the $13.42 price screens below the $16.51 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.

Follow Integra LifeSciences in your weekly email

Every Wednesday you see whether Integra LifeSciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments.

Show moreShow less

The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices.

In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair.

Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products.

Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems.

It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally.

Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Stock analysis

Integra LifeSciences Holdings (IART) currently trades at $13.42, while our model-based Fair Value estimate is $16.51, implying the stock looks roughly 19% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at medium.

Scenario range: $6.60 (bear) to $26.42 (bull), the price of $13.42 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Integra LifeSciences Holdings reported revenue of $1.6B in FY2025 versus $1.5B in FY2021, a compound +1.5%/yr. Reported net income was −$516M in FY2025.

Key figures

Market cap $1.0B Small · P/E ratio 78.9 · P/S ratio 0.63 · EPS (TTM) $0.1700 · Net margin 0.8% · Return on equity 1.2% · Return on assets (EBIT) 3.4% (5-year average) · Operating margin 6.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (medium confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 32% below its 52-week high and 51% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 23%, IART screens cheaper than that median.

Fair Value models

Bear $6.60 Fair Value $16.51 Bull $26.42
Price $13.42 · Upside +23.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.1453 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA $6.60 $16.51 $26.42 63
All 1 models by family
Multiples
EV/EBITDA $6.60 $16.51 $26.42 63

Open the full fair value analysis →

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 14
How much profit the company makes from its sales and capital
Quality Growth 24
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 15
Debt, balance sheet and risk of trouble
Investment 93
Does it invest with discipline instead of growing at any price?
Low Volatility 23
How calm the share price moves, does not count
Price momentum 36
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 47
Distance to the 52-week high, does not count
New shares 77
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 33/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
Start year 2020 (pandemic). Over 10 years: +6.4% a year
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
6.2% (2019) → 1.8% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch IART, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.

Compare Integra LifeSciences Holdings with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks

Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 36 · Bottom 25%
Fair Value upside +23.0% · Top 25%
Profitability
Return on equity (12 months) 1.2% · Below median
Return on assets −14.3% · Bottom 25%
Net margin (12 months) 0.8% · Below median
Operating margin (12 months) 6.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) 2.3% · Below median
Balance sheet
Debt / equity 1.66× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (12 months) 78.9× · Priciest 25%
P/B 1.01× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 0.63× · Cheapest 25%
EV/EBITDA 7.6× · Cheapest 25%
PEG 0.71× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)64 · sector 6
FUTURE (revenue growth)12 · sector 35
PAST (return on equity)5 · sector 17
HEALTH (low debt)17 · sector 98
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs IART
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs IART
DexCom, Inc DXCM $79.41 $87.35 +10% vs IART
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥197.22 +7% vs IART
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs IART
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs IART
Siemens Healthineers AG SHL €44.66 €34.95 −22% vs IART
Abbott Laboratories, ABT $109.93 $75.28 −32% vs IART
Medtronic plc MDT $101.80 $65.61 −36% vs IART
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs IART

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Integra LifeSciences Holdings: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Integra LifeSciences Holdings Fair Value". https://www.fairvalue-calculator.com/stock/IART

Frequently asked questions

Is Integra LifeSciences Holdings (IART) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $16.51 versus a price of $13.42, about +23% upside (undervalued).
What is the fair value of IART?
Our model-based fair value for Integra LifeSciences Holdings is $16.51 (as of Nov 5, 2026), built from audited fundamentals. The current price: $13.42.
What is the quality score of IART?
Integra LifeSciences Holdings has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Integra LifeSciences Holdings (IART)?
Our model-based price target is the fair value of $16.51 (as of Nov 5, 2026) from 1 valuation models. Cautious scenario $6.60, optimistic scenario $26.42. It is a calculation from audited fundamentals, not an analyst target.
What is the Integra LifeSciences Holdings stock forecast for 2026?
Our models put fair value at $16.51, about +23% upside versus a price of $13.42 (undervalued). Cautious scenario $6.60, optimistic scenario $26.42. The calculation is refreshed regularly with new filings.
What is the revenue of Integra LifeSciences Holdings (IART)?
Integra LifeSciences Holdings reported trailing-twelve-month revenue of about $1.7B (latest available figure, as of Nov 5, 2026).
What is the intrinsic value of Integra LifeSciences Holdings (IART)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Integra LifeSciences Holdings it is $16.51 per share (as of Nov 5, 2026), against a price of $13.42. It is the blended result of 1 valuation models in 1 family (Multiples).
Is Integra LifeSciences Holdings stock overvalued or undervalued in 2026?
As of Nov 5, 2026, IART trades below its calculated fair value: price $13.42, fair value $16.51, a gap of about +23% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IART?
No. The price is what the market pays today ($13.42); the fair value is what the company's own numbers justify ($16.51). For Integra LifeSciences Holdings the two are $3.09 per share apart. That gap is exactly why we show both numbers side by side.
How much is Integra LifeSciences Holdings worth?
The market values Integra LifeSciences Holdings at about $1.0B (market capitalisation, as of Nov 5, 2026). Per share that is $13.42; our models calculate a fair value of $16.51 per share.
What do the bullish and bearish scenarios say about IART?
Our models span a range for Integra LifeSciences Holdings: cautious scenario $6.60, base $16.51, optimistic $26.42 per share (as of Nov 5, 2026, price $13.42). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of IART?
Integra LifeSciences Holdings trades at a price-to-earnings ratio of 78.9 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $16.51 is built from several models across several years. Other multiples: PEG 0.7, P/B 1.0, P/S 0.6, EV/EBITDA 7.6.
What is the PEG ratio of IART?
The PEG ratio of Integra LifeSciences Holdings is 0.71 (P/E divided by earnings growth, as of Nov 5, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Integra LifeSciences Holdings (IART)?
Balance-sheet figures for Integra LifeSciences Holdings (as of Nov 5, 2026): return on equity 1.2%, debt of 1.66 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is IART from its 52-week high?
Integra LifeSciences Holdings trades at $13.42, about 32% below its 52-week high of $19.85 and 51% above the low of $8.90 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $16.51 is for.
Which stocks are comparable to Integra LifeSciences Holdings?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Integra LifeSciences Holdings stock attractive at the current price?
The data as of Nov 5, 2026: price $13.42, calculated fair value $16.51 (+23%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IART calculated?
We run Integra LifeSciences Holdings through 1 models from 1 family: Multiples. Every model gets the same audited fundamentals; the fair value of $16.51 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Integra LifeSciences Holdings currently trades 19% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Integra LifeSciences Holdings (IART)?
The closing price on Nov 6, 2026 was $13.42. Our model-based fair value is $16.51, about +23% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Integra LifeSciences Holdings right now?
The model range is unusually wide ($6.60 to $26.42). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Integra LifeSciences Holdings

How large is the market capitalisation of Integra LifeSciences Holdings (IART)?
The market capitalisation of Integra LifeSciences Holdings is $1.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Integra LifeSciences Holdings (IART)?
The price-to-sales ratio of Integra LifeSciences Holdings is 0.63 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Integra LifeSciences Holdings (IART)?
Earnings per share at Integra LifeSciences Holdings are $0.1700 (price ÷ EPS = P/E 78.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Integra LifeSciences Holdings (IART)?
The net margin of Integra LifeSciences Holdings is 0.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Integra LifeSciences Holdings (IART)?
The return on equity (ROE) of Integra LifeSciences Holdings is 1.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Integra LifeSciences Holdings (IART)?
On an EBIT basis the return on assets of Integra LifeSciences Holdings is 3.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Integra LifeSciences Holdings (IART)?
The operating margin of Integra LifeSciences Holdings is 6.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Integra LifeSciences Holdings (IART)?
Revenue at Integra LifeSciences Holdings is growing +2.3% versus a year earlier (3y avg +1.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Integra LifeSciences Holdings (IART)?
Earnings per share at Integra LifeSciences Holdings are growing +0.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Integra LifeSciences Holdings (IART) generate?
The free cash flow of Integra LifeSciences Holdings is −$45.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Integra LifeSciences Holdings (IART) carry?
The net debt of Integra LifeSciences Holdings is $1.8B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Integra LifeSciences Holdings in the live analysis

One click puts Integra LifeSciences Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.